Literature DB >> 221534

Adenylate cyclase in thymus-derived and bone marrow-derived lymphocytes from normal donors and patients with chronic lymphocytic leukemia.

J Mendelsohn, J Nordberg.   

Abstract

Lymphocytes were purified from peripheral blood of normal donors and patients with chronic lymphocytic leukemia (CLL) by Ficoll-Hypaque centrifugation. Adenylate cyclase activity, expressed as picomoles [(32)P]cyclic AMP generated per milligram protein per minute, was 57+/-4 in normals and 26+/-4 in CLL patients. Enzyme activity, expressed as picomoles [(32)P]cyclic AMP generated per 10(6) lymphocytes per minute, was 2.09+/-0.19 for normal lymphocytes and 1.10+/-0.16 for CLL lymphocytes. The differences between normal and CLL peripheral lymphocytes are highly significant (P < 0.001) with either method of calculating activity. Cyclic AMP levels (picomoles per 10(6) lymphocytes) also differed significantly: 1.38+/-0.29 for normals and 0.45+/-0.08 for CLL lymphocytes. Adenylate cyclase was assayed in lymphocytes enriched for bone marrow-derived (B) cells by removing E-rosetted thymus-derived (T) cells, and enriched for T cells by harvesting E-rosetted lymphocytes or by removing B cells with nylon wool absorption. Solutions to simultaneous equations gave the following calculated enzyme activities for pure B- and T-cell subpopulations (in picomoles [(32)P]cyclic AMP generated per milligram mg protein per minute): normal B, 196+/-22; normal T, 30+/-10; CLL B, 34+/-6; CLL T, 19+/-4. Thus. normal B-lymphocyte adenylate cyclase exceeds normal T-lymphocyte activity by more than sixfold, whereas in the case of CLL the enzyme activity in B lymphocytes is markedly reduced to levels comparable to T lymphocytes. The responses of lymphocytes to stimulation with the hormones prostaglandin E(1) and isoproterenol, and with NaF, were assessed. Compared with normal lymphocytes, enzyme activities were reduced in CLL lymphocytes incubated with these agents, but to a degree paralleling the reduced basal activities. Thus, the ratios between stimulated and basal adenylate cyclase levels in Ficoll-Hypaque-purified, normal lymphocytes were 2.3+/-0.1 after incubation with 10 muM isoproterenol, and 3.9+/-0.2 with 10 mM NaF, values which did not differ significantly from those obtained with CLL lymphocytes. When the enzyme activities calculated for purified T- and B-lymphocyte subpopulations were used to derive the stimulation ratios, the responses of normal and CLL T and B cells to these agents were also indistinguishable. The simplest explanation for these findings is a reduced number of normally responsive enzyme sites on the surface membranes of CLL lymphocytes, although alternative explanations are possible.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 221534      PMCID: PMC372059          DOI: 10.1172/JCI109405

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Characteristics of the cyclic nucleotide phosphodiesterases of normal and leukemic lymphocytes.

Authors:  W N Hait; B Weiss
Journal:  Biochim Biophys Acta       Date:  1977-03-29

Review 2.  Lymphocyte activation.

Authors:  H J Wedner; C W Parker
Journal:  Prog Allergy       Date:  1976

3.  Cyclic adenosine 3':5'-monophosphate levels and activities of related enzymes in normal and leukemic lymphocytes.

Authors:  T M Monahan; N W Marchand; R R Fritz; C W Abell
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

4.  An altered response to cyclic AMP stimulating hormones in intact human leukemic lymphocytes.

Authors:  P Polgar; J C Vera; A M Rutenburg
Journal:  Proc Soc Exp Biol Med       Date:  1977-04

5.  Catecholamine hormone receptors are reduced on chronic lymphocytic leukaemic lymphocytes.

Authors:  J R Sheppard; R Gormus; C F Moldow
Journal:  Nature       Date:  1977-10-20       Impact factor: 49.962

Review 6.  Cell kinetics in chronic lymphocytic leukaemia (CLL).

Authors:  P A Stryckmans; L Debusscher; E Collard
Journal:  Clin Haematol       Date:  1977-02

7.  Two novel stimuli of cyclic adenosine 3',5'-monophosphate (cAMP) in human lymphocytes.

Authors:  J P Atkinson; H J Wedner; C W Parker
Journal:  J Immunol       Date:  1975-10       Impact factor: 5.422

8.  Cyclic 3',5'-adenosine monophosphate phosphodiesterase in the thymus of normal and leukemic mice.

Authors:  L A Menahan; R G Kemp
Journal:  J Cyclic Nucleotide Res       Date:  1976 Nov-Dec

9.  Differences in effect of isoproterenol stimulation on levels of cyclic AMP in human B and T lymphocytes.

Authors:  P Niaudet; G Beaurain; M A Bach
Journal:  Eur J Immunol       Date:  1976-11       Impact factor: 5.532

10.  Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in normal and chronic lymphocytic leukemia lymphocytes.

Authors:  N S Scher; F Quagliata; V G Malathi; D Faig; R A Melton; R Silber
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

View more
  4 in total

1.  Low sodium diet corrects the defect in lymphocyte beta-adrenergic responsiveness in hypertensive subjects.

Authors:  R D Feldman; W J Lawton; W L McArdle
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

2.  Direct relationship between mononuclear leukocyte and lung beta-adrenergic receptors and apparent reciprocal regulation of extravascular, but not intravascular, alpha- and beta-adrenergic receptors by the sympathochromaffin system in humans.

Authors:  S B Liggett; J C Marker; S D Shah; C L Roper; P E Cryer
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

3.  Effect of high doses of somatostatin on adenylate cyclase activity in peripheral mononuclear leukocytes from normal subjects and from acute leukemia patients.

Authors:  M Peracchi; F Bamonti-Catena; B Bareggi
Journal:  Experientia       Date:  1988-07-15

4.  Biphasic adrenergic modulation of beta-adrenergic receptors in man. Agonist-induced early increment and late decrement in beta-adrenergic receptor number.

Authors:  J F Tohmeh; P E Cryer
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.